4-[1-hydroxy-5-(2-fluoropyridin-4-yl)-4-(3-trifluoromethylphenyl)-1H-imidazol-2-yl]piperidine-1-carboxylic acid benzyl ester | 189442-56-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 4-[1-hydroxy-5-(2-fluoropyridin-4-yl)-4-(3-trifluoromethylphenyl)-1H-imidazol-2-yl]piperidine-1-carboxylic acid benzyl ester
• 英文别名: 4-[1-hydroxy-5-(2-fluoropyridin-4-yl)-4-(3-trifluoromethyphenyl)-1H-imidazol-2-yl]piperidine-1-carboxylic acid benzyl ester；benzyl 4-[5-(2-fluoropyridin-4-yl)-1-hydroxy-4-[3-(trifluoromethyl)phenyl]imidazol-2-yl]piperidine-1-carboxylate
• CAS: 189442-56-6
• 化学式: C₂₈H₂₄F₄N₄O₃
• 分子量: 540.517
• InChiKey: BVPUTSDSQIFHLC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.6
• 重原子数：
  39
• 可旋转键数：
  6
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  80.5
• 氢给体数：
  1
• 氢受体数：
  9

反应信息

• 作为反应物：
  描述：

  4-[1-hydroxy-5-(2-fluoropyridin-4-yl)-4-(3-trifluoromethylphenyl)-1H-imidazol-2-yl]piperidine-1-carboxylic acid benzyl ester 在 盐酸 、 titanium(III) chloride 作用下， 以 甲醇 为溶剂， 反应 3.0h， 生成 5-(2-fluoropyridin-4-yl)-4-<3-(trifluoromethyl)phenyl>-2-<4-(N-(benzyloxycarbonyl)piperidinyl)>imidazole
  参考文献：
  名称：

  Design and Synthesis of Potent, Selective, and Orally Bioavailable Tetrasubstituted Imidazole Inhibitors of p38 Mitogen-Activated Protein Kinase

  摘要：

  Novel potent and selective diarylimidazole inhibitors of p38 MAP (mitogen-activated protein) kinase are described which have activity in both cell-based assays of tumor necrosis factor-alpha (TNF-alpha) release and an animal model of rheumatoid arthritis; The SAR leading to the development of selectivity against c-Raf and JNK2 alpha 1 kinases is presented, with key features being substitution of the 4-aryl ring with m-trifluoromethyl and substitution of the 5-heteroaryl ring with a a-amino substituent. Cell-based activity was significantly enhanced by incorporation of a 4-piperidinyl moiety at the 2-position of the imidazole which also enhanced aqueous solubility. In general, oral bioavailability of this class of compounds was found to be poor unless the imidazole was methylated on nitrogen. This work led to identification of 48, a potent (p38 MAP kinase inhibition IC50 0.24 nM) and selective p38 MAP kinase inhibitor which inhibits lipopolysaccharide-stimulated release of TNF-alpha from human blood with an IC50 2.2 nM, shows good oral bioavailability in rat and rhesus monkey, and demonstrates significant improvement in measures of disease progression in a rat adjuvant-induced arthritis model.

  DOI：

  10.1021/jm9805236
• 作为产物：
  描述：

  3-(三氟甲基)苯甲酰氯 在 乙酸铵 、 盐酸 、 亚硝酸特丁酯 、 溶剂黄146 、 三乙胺 、 lithium diisopropyl amide 作用下， 以 乙醇 、 二氯甲烷 为溶剂， 反应 4.83h， 生成 4-[1-hydroxy-5-(2-fluoropyridin-4-yl)-4-(3-trifluoromethylphenyl)-1H-imidazol-2-yl]piperidine-1-carboxylic acid benzyl ester
  参考文献：
  名称：

  Design and Synthesis of Potent, Selective, and Orally Bioavailable Tetrasubstituted Imidazole Inhibitors of p38 Mitogen-Activated Protein Kinase

  摘要：

  Novel potent and selective diarylimidazole inhibitors of p38 MAP (mitogen-activated protein) kinase are described which have activity in both cell-based assays of tumor necrosis factor-alpha (TNF-alpha) release and an animal model of rheumatoid arthritis; The SAR leading to the development of selectivity against c-Raf and JNK2 alpha 1 kinases is presented, with key features being substitution of the 4-aryl ring with m-trifluoromethyl and substitution of the 5-heteroaryl ring with a a-amino substituent. Cell-based activity was significantly enhanced by incorporation of a 4-piperidinyl moiety at the 2-position of the imidazole which also enhanced aqueous solubility. In general, oral bioavailability of this class of compounds was found to be poor unless the imidazole was methylated on nitrogen. This work led to identification of 48, a potent (p38 MAP kinase inhibition IC50 0.24 nM) and selective p38 MAP kinase inhibitor which inhibits lipopolysaccharide-stimulated release of TNF-alpha from human blood with an IC50 2.2 nM, shows good oral bioavailability in rat and rhesus monkey, and demonstrates significant improvement in measures of disease progression in a rat adjuvant-induced arthritis model.

  DOI：

  10.1021/jm9805236

文献信息

• Substituted imidazoles having anti-cancer and cytokine inhibitory
  申请人：Merck & Co., Inc.

  公开号：US05717100A1

  公开（公告）日：1998-02-10

  Compounds represented by formula I: ##STR1## are disclosed. AR represents an aromatic group containing 6-10 atoms; and ##STR2## represents a 4 to 6 membered non-aromatic heterocycle containing only one N atom. A pharmaceutical composition is also included. Methods of treating cancer and cytokine mediated diseases are also included.

  公式I所代表的化合物如下所示：##STR1##。其中，AR代表含有6-10个原子的芳香基团；而##STR2##代表一个仅含有一个N原子的4至6元非芳香杂环。还包括一种药物组合物。还包括治疗癌症和细胞因子介导疾病的方法。
• SUBSTITUTED IMIDAZOLES HAVING ANTI-CANCER AND CYTOKINE INHIBITORY ACTIVITY
  申请人：Merck & Co., Inc.

  公开号：EP0854870B1

  公开（公告）日：2009-06-10
• US6083949
  申请人：——

  公开号：——

  公开（公告）日：——
• US06083949
  申请人：——

  公开号：——

  公开（公告）日：——
• US6083949A
  申请人：——

  公开号：US6083949A

  公开（公告）日：2000-07-04